Testing a New Cancer Treatment for Advanced Melanoma and Other Tumors

Plain-English translation of NCT07027488 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called for people with advanced melanoma or other solid tumors that have stopped responding to previous treatments. The study will gradually increase the dose of this medication given as an IV infusion to find the safest and most effective dose. Researchers will watch carefully for side effects and signs that the treatment is helping.

Many patients with advanced melanoma and other cancers stop responding to current immunotherapy treatments, and doctors need new options to help them. This medication is designed to work differently and may help patients whose cancers have become resistant to standard therapies.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have advanced melanoma that has grown despite prior immunotherapy treatment, or another advanced solid tumor that has received at least one prior treatment
you have measurable cancer visible on imaging scans
you are in good enough health to participate, as confirmed by blood work and your doctor's assessment
you are able and willing to use contraception if you can become pregnant or have a partner who can

You likely don't qualify if…

you have a weakened immune system or a history of HIV, hepatitis B, or hepatitis C
you have had an organ or bone marrow transplant
you have an active autoimmune disease requiring ongoing treatment with steroids or immunosuppressive drugs
you have untreated cancer that has spread to your brain or spinal fluid
you have severe diarrhea or bowel inflammation at the time of enrollment

What participation looks like

You would come to the clinic to receive the medication as a 30-minute intravenous infusion, given every 2 to 3 weeks based on your body weight and the study phase. You will have screening visits to confirm you qualify, regular treatment visits, safety blood tests, and imaging scans to check how your cancer is responding. After you finish receiving the medication, you'll have follow-up visits at 30, 60, and 90 days, and then longer-term check-ins to monitor your health and track how you are doing.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Trial locations(1 site)

United States

Yale University, New Haven, Connecticut